EuropaBio’s State of European Biotech Address Review of year past & future outlook | 2014–2015
The European Association Bioindustries The European Association for for Bioindustries
2
Review of year past & future outlook
3
Review of year past & future outlook
EuropaBio at a Glance 5 The State of European Biotech Address 6 Talking Benefits: Biotech for Life 8 The State of Healthcare Biotech in Europe 10 The State of Agricultural Biotech in Europe 14 The State of Industrial Biotech in Europe 18 EuropaBio Team 22 EuropaBio Members 24
4
Review of year past & future outlook
EuropaBio at a Glance We are EuropaBio, the European Association for Bioindustries, created in 1996 to promote an innovative and dynamic biotechnology-based industry in Europe.
Our membership is composed of 60 corporate members, 13 associate members and bio regions, and 17 national biotechnology associations representing over 1800 European biotech SMEs. EuropaBio has a Management Board made up of representatives of member companies and national associations. The Board is supported by the secretariat staff members who carry out day to day activities under the management of the Secretary General. The three main sectors of biotechnology are represented through Councils: Healthcare (Red Biotech), Industrial (White Biotech) and Agri-Food (Green Biotech). Through our National Associations Council and horizontal SME Platform, we represent more than 1800 biotech small and medium-sized enterprises across Europe. In an independent survey by APCO and EurActiv in 2013, EuropaBio was ranked as the most effective trade association in Brussels.
Trade Association in BRUS BRUSSELS SSELS 2 0 1 3
5
Review of year past & future outlook
We are committed to the socially responsible use of biotechnology to improve quality of life, to prevent, diagnose, treat and cure diseases, to improve the quality and quantity of food and feedstuffs and to replace oil-based products and processes with biobased products and processes. Our members adhere to common core ethical values that guide our work.
Review of year past & future outlook
Carlo Incerti
Footnotes: ‘2014: A new benchmark year for biotech IPOs’, EY Changing Business of Life Sciences Blog, January 9, 2015 2 ‘The IPO wave continues’, European Biotechnology Magazine, Spring Edition, Vol. 14, 2015, p. 24 3 Idem 4 European Biotech Stock Market Monitor, BIOCOM AG 5 ‘UK life sciences hit 7-year high’, Financial Times, October 6, 2014 6 ‘Biotechnology in Europe: The Tax, Finance and Regulatory Framework and Global Policy Comparison’, EY and EuropaBio joint report, page 7. The report can be downloaded on www.europabio.org. 1
Nathalie Moll
6
The State of European Biotech Address Enabling a European industry at full sail to overcome rough seas. By: Carlo Incerti, EuropaBio Chair & Nathalie Moll, EuropaBio Secretary General
the EU ‘becomes the world’s biotech research hub while innovative products and processes and the jobs and growth that go with their development, will be found elsewhere’6. Other regions are highly competitive in terms of attracting biotech companies and ensuring they get their products on the market. One main setback in Europe is a less predictable and in some sectors, non-science-based regulatory framework, evidenced most recently by the move away from the Single Market in amending the Directive on cultivation of GMOs in Europe. The EU also needs to do more to ensure the excellent funding and tailored market pull measures offered by other parts of the world are available to biotech companies, and that concrete measures are put in place to ensure more equitable access to biotech products and processes for patients, farmers and consumers.
A HUB FOR LIFE SCIENCES ACROSS THE CHANNEL One of the main actors in the financing upswing has been the UK, which showed its confidence in the industry by appointing a former healthcare entrepreneur, George Freeman, as its first ever Life Sciences Minister. The government’s efforts to promote investment in biotech have contributed to making the country the top European destination in terms of life sciences fundraising, with almost one billion Euros capital raised by the middle of 20145.
FUTURE IMPERFECT? As we set out in our industry Manifesto a year ago, this European Commission and Parliamentary term will determine the success of Europe’s biotech industry. The term is focused on growth, jobs and investment. No other industry is better placed to realise these goals from within Europe. Europe has the brainpower in its science, the willingness in its biotech companies and entrepreneurs and patients, farmers and consumers waiting for solutions. The question is: will our leaders fix the remaining stumbling blocks and enable biotech to deliver its results in terms of societal solutions, growth and jobs here in Europe, or not? As our industry’s leading association and voice at EU level, we look forward to working with all stakeholders to ensure this opportunity is not missed.
A QUESTION MARK OVER EUROPE Although a number of other individual EU countries have also done exceptionally well in the past 12 months, a similarly strong and coherent political commitment may be more difficult to find at European level, where the risk remains that
7
Review of year past & future outlook
AN INDUSTRY AT FULL SAIL ‘Unprecedented. Record-setting. Red-hot.’ At the start of 2015 EY used these words to characterise the US IPO and investment climate during the previous year1. This confidence and optimism seems to have caught on across the Atlantic as well, with 2014 having been an exceptional year in terms of investment in European biotech. The European stock-exchanges saw almost two and a half billion Euros being invested in new biotech companies (25% more compared to 2013) and 15 companies going public in 2014 (three times more than in 2013)2. This meant that by the end of the year there were 150 publicly listed biotech companies worth 66 billion Euros in Europe, showing an industry at full sail and past the economic setbacks of previous years3. This trend has continued with another seven IPOs in the first quarter of 20154.
Talking Benefits: Biotech for Life EuropaBio is showcasing the benefits and value of biotechnology through annual flagship initiatives as well as social media.
Review of year past & future outlook
#Biotech4Life The whole team at EuropaBio has joined forces to invigorate our social media presence. LinkedIn, Twitter and Facebook are now updated on a daily basis with the latest news on #biotech and with live comments during internal/external events. Check them out and engage with us using #Biotech4Life!
The 2014 SME Awards judges, winners (French Erytech Pharma and Italian Bio-on) and finalists (Danish Biosyntia, British Autifony Therapeutics, and Dutch BBB Therapeutics)
5th Most Innovative EU Biotech SME Award On 8 October, EuropaBio opened the Euronext markets in Brussels to mark the presentation of the 5th Most Innovative EU Biotech SME Award. At the end of the ceremony which had a strong focus on access to finance for European biotech small and medium-sized enterprises (SMEs), Antti Peltom채ki, Deputy Director General of DG Entre-
prise & Industry, proudly rewarded two innovative biotech SMEs: Erytech Pharma, a French healthcare SME developing cancer therapies, and Bioon, an Italian industrial SME creating bioplastics, as the most innovative biotech SMEs in Europe in 2014.
8
2nd edition of the European Biotech Week
Following on from the great success in 2013, the 2nd edition of the European Biotech Week took place between 6 – 12 October 2014. With 100+ events and activities in 14 European countries, there was something for anyone with a curious mind and an interest in biotech. Visit www.biotechweek.org and have a look inside the magazine “Unraveling the Potential of Biotechnology” to learn more!
More than 100 events and activities took place across Europe during Biotech Week 2014
9
Review of year past & future outlook
Opening of the 2014 European Biotech Week exhibition at the European Parliament
The State of Healthcare Biotech in Europe Facing challenges through innovation and ambition.
Review of year past & future outlook
Miriam Gargesi, EuropaBio Director of Healthcare Biotechnology
Thanks to the application of modern biotechnology, progress made over the past decade in the understanding of the molecular processes behind diseases have enabled scientists to identify new targets for the development of medicines and make new cutting-edge therapies available to patients. Amongst these, progress in studying rare diseases has often led to medical advances offering unexpected leads for more common diseases. Other examples of new concepts enabled by the application of biotechnology include improved diagnostic techniques for use in personalised medicine, which have already increased survival rates for certain forms of cancers.
a select number of vectors for a rare immune deficiency called Wiskott - Aldrich syndrome were later on tested in other immune disorders and eventually used to treat conditions such as leukaemia and Leber’s congenital amaurosis1. In order to continue to foster such breakthroughs, European and national policy makers must tackle remaining challenges to the sustainability of the healthcare biotech sector. On the one hand, we see how fundamental workable and stable regulatory frameworks as well as the availability of funding are to the upstream stages of the product life-cycle (i.e. discovery, product development and manufacturing). On the other hand, it is clear that the downstream stages of the product life-cycle (i.e. commercialisation of products, access to patients and continued investment in research) are traditionally more affected by market-related factors, such as Health Technology Assessment, distribution and pricing policies. It is important that legislative developments as well as market-related policies are implemented in such a way that does not discourage free market competition and incentives for companies to make high-risk investments in the discovery and production of new treatments.
By tackling the underlying cause of disease and not simply relieving the symptoms, the innovative treatments that derive from the application of biotechnology are allowing patients to experience better health outcomes. This in turns allows them to stay healthy and active for longer thus reducing pressure on healthcare services. Despite the incredible benefits brought about by the application of healthcare biotech, few ever make it to mainstream media where the healthcare industry is mainly discussed in terms of the cost of treatments and effects on social security budgets rather than in terms of the benefits it offers. What is often forgotten is that many preventive biotech therapies and treatments are highly cost-effective. They represent a high social return for the investments made by public authorities in terms of healthcare expenditure, and are often “gate openers� for innovative medical research. A telling example of the latter can be taken from the rare disease space: the insertion of
Given the complex landscape of challenges faced by the healthcare biotech industry, we continue to call for a holistic approach by decision-makers at both the EU and national level that integrates health, economic and industrial policies and addresses the whole value chain. Policies addressing the economics of supply and demand, supporting incremental innovations throughout the market life-cycle, accelerating uptake of biologics into general medical practice
10
Review of year past & future outlook
Miriam Gargesi
and attracting inward investment in all phases of the innovation process must be put in place and be coherent and supportive of one another. Maintaining a high level of ambition is crucial if we want to keep accelerating the translation of science into highly effective biologic medicines destined to respond to unmet medical needs, and if we want to realise our goal of potentially curing, and at least dramatically transforming, the lives of European patients.
Footnotes European Medicines Agency 20th anniversary book, p. 29 – available online at: http://tinyurl.com/n9ljedr 1
11
Achievements
Review of year past & future outlook
With the new European Commissioners and Members of the European Parliament starting their term in 2014, the Healthcare Biotech Unit of EuropaBio and its members focused on ensuring sufficient information was developed to describe the science and potential behind biologic medicines and the very specific hurdles faced by
Briefing Paper on the EU Clinical Trials Regulation Key outcomes and impact on clinical research
their producers. The following publications were discussed with stakeholders at European and national level over the past year and are the basis of our ongoing efforts to clarify one of the most promising technologies to treat and hopefully cure patients while addressing the pressing needs of healthcare costs in Member States.
EuropaBio Guide on Biosimilars in Europe
EuropaBio White Paper
Realising the potential of personalised medicine in Europe
When Science Meets Policy
Briefing paper on the EU Clinical Trials Regulation To assist its members, EuropaBio issued a briefing paper on the new EU Regulation on Clinical Trials of April 2014. It clarifies how new provisions of the Regulation impact clinical research conducted by healthcare biotech companies and which are especially complex for SMEs. http://tinyurl.com/qb6scml
“Biosimilars in Europe” As more biosimilars enter the market, EuropaBio developed a new guide that offers an introduction to biosimilar medicines, including their contribution to healthcare systems; their regulatory approval pathway in Europe; and the EuropaBio policy position about the naming, labelling and terms of use for these types of biologic medicines. http://tinyurl.com/nvy6hgw
Policy recommendations on “Realising the Potential of Personalised Medicine in Europe” As discussions around more targeted healthcare intensify, EuropaBio published its second white paper on personalised medicines. This guide sheds light on the challenges for developing and delivering personalised medicines to patients. It also provides detailed policy recommendations and calls for action to our decision makers. http://tinyurl.com/nmelfxv
12
Development process of
Orphan Medicinal Products
Valuing Healthcare Biotechnology in Europe: EuropaBio’s perspective
Deerfield Institute EuropaBio Report on REGULATORY AND HTA SCIENTIFIC ADVICE FOR SMALL AND MEDIUM ENTERPRISES
March 2015
1
EuropaBio-EFPIA Joint Task Force on Rare Diseases and Orphan Medicinal Products
“Valuing Healthcare Biotechnology in Europe: EuropaBio’s perspective” brochure EuropaBio issued the first ever report detailing the value of healthcare biotechnology in Europe for patients, the economy and European society at large to coincide with the new European Commission and Parliament in mid 2014. The resulting brochure describes the complex life-cycle of biologic medicines and the challenges faced by European industry due to global competition and national level patient-access hurdles among other issues. http://tinyurl.com/nusgmw7
Survey on the current state of regulatory and health technology assessment advice to SMEs, in collaboration with the Deerfield Institute As representatives of thousands of biotech SMEs in Europe, it is important for EuropaBio to fully grasp the issues these companies face in bringing products to the market, such as tackling Health Technology Assessments. The findings of a survey run by EuropaBio suggest early regulatory scientific and HTA advice may help SMEs to better prepare and manage their clinical programs toward facilitating both regulatory approval and positive HTA recommendations, and therefore contribute to their increased competitiveness. http://tinyurl.com/qc2jm94
vision
“Development Process of Orphan Medicinal Products” and “Our 2020 vision” 2015 marks the 15 years anniversary of the entry into force of the European Regulation on Orphan Medicinal Products, one of the most successful pieces of legislation. To reflect on this, EuropaBio issued two papers taking stock of the remaining challenges in the development of therapies for rare conditions and outlining the conditions needed for industry to continue to innovate in Europe.1 http://tinyurl.com/p5k67fg http://tinyurl.com/pqmczl2
1
Realised in collaboration with the European Federation of Pharmaceutical Industries and Associations (EFPIA)
13
Review of year past & future outlook
Our 2020
The State of Agricultural Biotech in Europe Time to think again.
Review of year past & future outlook
Beat Späth, EuropaBio Director of Agricultural Biotechnology
agreed EU laws and procedures was confirmed by Court and WTO rulings. The system for cultivation authorisations has never been correctly implemented, and several national bans were confirmed to be illegal. As a result, most arable crop farmers in the EU have always been denied the freedom to choose which safe products to grow. In March 2015, a legislation was adopted which enables Member States to ban their farmers even more easily from growing safe products approved at EU level. Apart from confirming Europe’s direction towards becoming a museum of world farming, this sets a very bad precedent for the internal market and science-based decision-making. Now we know that this was not an isolated initiative for cultivation only. Which safe products will be banned next?
SACRIFICING THE INTERNAL MARKET FOR AGRICULTURAL IMPORTS As one of its priorities, the EU Commission has recently proposed to give Member States a license to ban the use of GMOs that are approved for import into the EU. This would end the EU internal market and lead to a “Europe à la carte”. The system, which is currently strict but practicable on paper, became dysfunctional in practice, as approvals of safe products were put on hold for 18 months before April 2015. The logical way to fix it would be simply by authorising safe products and implementing the current legislation, as is common place on an almost daily basis for the many other categories of regulated products. WHY EUROPE NEEDS GMO APPROVALS: WEIGHING UP THE SOYBEANS GMOs are an integral part of our daily lives and the EU benefits hugely from the trade of genetically modified (GM) crop commodities. Our clothes and bank notes are made with GM cotton, and each year, our farm animals eat an amount of GM soybeans roughly equivalent to the combined weight of all EU citizens, an incredible number of almost 34 million tonnes. Livestock farmers, and ultimately all of us, are paying unnecessarily high prices because the EU system for GM import authorisations has become dysfunctional. Without GMOs, Europe’s big livestock farming sector would collapse, forcing farmers out of business, replacing local production with more meat imports to Europe, and further increasing prices for consumers.
ESCAPING THE POLITICS OF FEAR I hope that 2015 will mark a shift towards coherent policy-making. Many politicians seem to have given up to unfounded concerns. But voting against or otherwise blocking or delaying the authorisation of safe products will not change but only solidify these unfounded concerns, as will efforts to create policy-based facts rather than fact-based policies. The EU is in a vicious circle of a lack of approvals and decreased trust: no vote - no trust, no trust - no vote. This negative precedent of “politics over science” has a major and concrete impact on companies’ decisions where to invest (beyond the biotech field). Public researchers also face protests and illegal destructions of field trials, and radical activists even invaded the European Food Safety Authority with smoke bombs. Let’s make sure that facts and freedom of choice prevail over scaremongering.
A HISTORY OF INSTITUTIONAL LAW BREAKING The lack of institutional respect for democratically
14
Review of year past & future outlook
Beat Sp채th
The most obvious and easy generator of innovation, jobs and growth is to approve safe new products in reasonable timelines.
world population. GMOs with direct consumer benefits (such as plants producing healthier oils) are currently entering the market. Where farmers are given the choice, millions decide to buy and grow biotech seeds. The number of farmers growing GM crops today is larger than all farmers in the EU, and they grow GMOs on an area larger than the entire EU arable land. Meanwhile the EU, with a cradle of GMO innovation in Ghent, Belgium, has turned from leader to laggard. Time to think again!
TIME TO THINK AGAIN Public perception is gradually improving, especially where media reduce their pickup of unfounded scaremongering and where politicians dare tell the truth: genetic modification causes no harm whatsoever and is simply a targeted tool to improve plants, which have helped farmers grow more sustainably to feed the growing
15
Achievements 17 GM products for import approved
Review of year past & future outlook
In April 2015, the European Commission authorised imports of 17 GM products which had been pending on average 6.5 years from the time of submission until the final authorisation. There are now over 40 additional GM applications for import waiting in the system. EuropaBio has called on the Commission* to continue granting Europe’s livestock farmers freedom of choice by approving products in a timely and predictable fashion. EuropaBio also published regular updates on the status of ‘Undue Delays’** of GMO import authorisations with the aim of highlighting what remains to be done. * http://tinyurl.com/nekmbr9 ** http://tinyurl.com/o3asmcr
Europe à la carte? In April 2015, the European Commission presented a proposal to allow individual Member States to ban the use of imported GMOs on their territories on the basis of non-scientific criteria. EuropaBio organised the first high level event on the shocking proposal that was attended by over 100 representatives from EU institutions and Member States, the food and feed supply chain as well as NGOs and media, with a special keynote speech delivered by Arūnas Vinčiūnas, Head of Cabinet of Commissioner for Health and Food Safety. Participants discussed how the proposal could affect international trade and what it could mean for Europe’s internal market, as well as whether it sets a precedent for a ‘Europe à la carte’ that could spill over to other sectors. The conclusion by the food and feed chain actors and third countries was that they could not see how this proposal fits with the Commission’s jobs and growth and better and smart regulation agendas or how it can actually be implemented. At the event EuropaBio also launched the video of the journey of Mr. Maize, a genetically modified maize from Brazil, to Europe.*
Making a point about facts In an effort to put the new proposal to allow Member States to ban the use of GMO imports into perspective, EuropaBio published facts about the quantity of GMOs imported into the EU* and used in individual Member States**, highlighting that even Member States that vote against GMO approvals, are heavily dependent on GMO trade. In addition, in order to familiarise stakeholders with the GMO authorisation process***, EuropaBio prepared an infographic explaining how the approval process for import of GMOs in the EU is currently working. * http://tinyurl.com/ohbvokv ** http://tinyurl.com/owkgnkn *** http://tinyurl.com/pgnkcty
* http://tinyurl.com/nq5hs8j
16
THE EUROPEAN COMMISSION “The main conclusion to be drawn from the efforts of more than 130 research projects, covering a period of more than 25 years of research, and involving more than 500 independent research groups, is that biotechnology, and in particular, GMOs, are no more risky than conventional plant breeding technologies.” A Decade of EU-funded GMO Research (2001-2010), 2010
#TradeTalk
Ever wondered what people say about GMO safety?* EuropaBio launched a new eye-opening factsheet on what European leaders and worldwide renowned institutions say about GMOs.
With the aim of getting a conversation going around the EU’s dependency on GMO imports, EuropaBio launched a blog section at the beginning of March 2015 called Trade Talk* dedicated to the news and views on GM crop imports from around Europe.
And what about us? How gene’ophobic are we? Recent polls show that a majority of EU citizens does not feel strongly about genetic engineering. Our infographic on public perception** picks up the latest data on the position of Europeans towards GMOs.
* http://growingvoices.eu/blog/tradetalk/
* http://tinyurl.com/oy4uayo
New study on benefits from IP rights for agricultural innovation In November 2014, EuropaBio launched a new study* on actual benefits resulting from intellectual property rights applied in agricultural innovation. The study was conducted on the case of Ogura, an oilseed rape hybridisation technology developed by the French Public Research Institute INRA. The study showed that the fact that Ogura had been protected with the help of intellectual property allowed the creation of €1.2 billion in economic benefits to society — a significant boon for the French economy. *http://tinyurl.com/m79mjay
17
Review of year past & future outlook
What is said and thought of GMOs
The State of Industrial Biotech in Europe Policy into practice – en route towards Bioeconomy 2.0
Review of year past & future outlook
Joanna Dupont-Inglis, EuropaBio Director of Industrial Biotechnology
With the dust now settling after the arrival of the new Juncker Commission last September, policy opportunities and challenges are becoming clearer for biobased industries. President Juncker’s new approach, aimed at slicing through well-established policy silos holds promise for cross cutting issues, such as the development of a competitive and sustainable bioeconomy.
only partially implemented after their publication in 2011. Experts in biobased are exploring the possibilities held by public procurement and are increasingly examining the fine detail on regulatory and other barriers to establishing a dynamic internal market. Access to competitively priced feedstock remains a concern with an ongoing need for appropriate rural development and regional funding programmes to help establish and support new value chains and partnerships. In this respect, championing agricultural productivity and sustainability will be key, as well as putting in place measures and schemes to support collection, storage and transportation of renewable raw materials, especially agricultural residues.
Although several important milestones were reached during Barosso II, including the launch of the 3.7 billion biobased industries public private partnership, leaders in this field continue calling for a more holistic, coherent, supportive and predictable approach towards bioeconomy policy making. The benefits of EU biobased industries should resonate well enough among thought leaders within the new Commission for their potential to tackle climate change while reducing dependence on fossil-carbon imports, and creating jobs and growth. Now it’s time for the Juncker Commission to put the necessary measures in place to retain and attract greater investment in this sector.
Accessing combined funding for the construction of new demonstration and flagship biorefineries remains a critical issue to help bridge the innovation ‘valley of death’ and reverse the migration trend of Europe’s leading industrial biotech pioneers abroad to more supportive and enabling environments. Facilitating such access will be integral to attracting future private investment and to overcoming the dependence on the fossil-based “business as usual” approach. As yet, however, industry remains baffled by the complexities, inconsistencies and overwhelming administrative labyrinth of combining regional, national, Horizon 2020 and EIB funding, amongst other budget lines. Simplifying and harmonising these funding rules and aligning basic funding principles will be fundamental to boosting green jobs, growth, markets and biobased industry confidence in Europe.
Furthermore, the backlash to the Commission’s announcement of the withdrawal of the Circular Economy proposal and the subsequent show of support, from the European Parliament, to Member States, industry and NGOs, has highlighted the demand for more sustainable, renewable products and processes, including biobased. Biobased industries are united in their long term wish for the deployment of the demand-side stimulation measures, finalised by the Lead Market Initiative group on biobased products, and left
18
Review of year past & future outlook
Joanna Dupont-Inglis
President Juncker has set the scene for change through a bold move to transform the way in which his Commissioners will work together across policy sectors. Bold political moves are exactly what is needed to get the EU back on track and to deliver solutions to tackle the combined threats of climate change, energy and food security, while ensuring sustainable economic recovery.
Industrial biotech and biobased industries will play a critical role on the journey towards delivering these objectives. But time is short and trans policy vision and action are needed to ensure that the new Commission and the Member States help provide a ‘make’ rather than ‘break’ moment for Europe’s leading Industrial Biotech Sector.
19
Review of year past & future outlook
Achievements
Former EC President José Manuel Barroso and Commissioners Maire Goeghegan Quinn and Neelie Kroes at the launch of the European Joint Undertaking (JU) on Biobased Industries (BBI)
European Joint Undertaking (JU) on Biobased Industries (BBI)
Formation and launch of the European Bioeconomy Alliance
On 9 July 2014 EU and industry leaders launched a new European Joint Undertaking (JU) on Biobased Industries (BBI). The aim was to trigger investments and create a competitive market for biobased products and materials sourced locally and “Made in Europe”, tackling some of the EU’s biggest societal challenges. The launch of the BBI JU was a milestone for EuropaBio whose board held the first meeting with the Barroso II Commission calling for a Joint Undertaking with the then Research and Innovation Commissioner, Maire Goeghegan Quinn. EuropaBio subsequently played a formative role in the development and realisation of the initiative as providers of cutting edge technology, adding value to numerous other leading European sectors.
On 4 February 2015 in the European Parliament, EuropaBio and a group of other associations launched the European Bioeconomy Alliance. The Alliance seeks to help develop a world leading, dynamic and competitive bioeconomy, based on renewable raw materials in the EU. It pools the expertise and efforts of many actors throughout the value chain, including the EU’s farmers, foresters, starch, sugar, bioethanol and plant derived oil producers as well as many other biobased industries. Furthermore, the alliance calls for the development of a holistic, coherent and harmonised framework across a range of policy fields including agriculture, forestry, marine, industrial, climate, environment, energy, research, innovation and regional development.
http://bbi-europe.eu
http://bioeconomyalliance.eu
20
The BIO-TIC project – leveraging €2.8million for tackling challenges to industrial biotech The BIO-TIC project aims to raise awareness and understanding of the benefits of industrial biotech, drive technological innovation and build solid foundations for this growing, high value sector in the EU. Over the past three years BIO-TIC has gathered information, insights and expertise from across Europe on the barriers and solutions to boosting uptake of this key enabling technology. Highlights of the past year include: 5 business case workshops attended by 157 participants held throughout Europe on biobased chemical building blocks, CO2 as a feedstock for white biotech, biopolymers, 2G ethanol and bio jetfuels and on biosurfactants. A revamped website with (1) clear, straightforward info on IB basics, its benefits and innovative examples of IB use; and (2) country profiles for what is going on in terms of IB in the Member States;
www.industrialbiotech-europe.eu
Record attendance at the biggest ever European IB event: the European Forum on Industrial Biotech and the Bioeconomy 2014 (EFIB) In 2014 EFIB offered unparalleled opportunities to showcase the benefits and breakthroughs in industrial biotech to a high level audience of business and policy decision makers and thought leaders. In 2014 EFIB brought together over 700 participants from 39 countries with around 50% of attendees of C, Board, Director, President of VP levels. 2015 will see EFIB returning to Brussels, its place of origin with a special focus on the potential of Industrial Biotech to provide world leading, sustainable solutions to the challenges of developing a circular economy and mitigating the impacts of climate change.
EFIB 2014, where policy meets industry, was held in Reims, France
http://www.efibforum.com
21
Review of year past & future outlook
The BIO-TIC final conference took place at the Royal Flemish Academy for Sciences and Arts –KVAB on 23 June 2015 and was entitled ‘From bugs to business – Unlocking the Bioeconomy in Europe’. The conference saw the official launch of the BIO-TIC final roadmap containing a comprehensive set of recommendations to boost the technology in Europe. It attracted over 120 participants from the fields of policy making, civil society, industry and academia and included an exhibition of biobased products enabled by IB. The conference also showcased the tools developed during the project. The conference was followed by a visit of the Bio Base Europe Pilot Plant on the next morning.
EuropaBio Team Nathalie Moll Secretary General
Review of year past & future outlook
@NathalieMoll
Delphine Carron
Christine Devaux
Joanna Dupont - Inglis
Regulatory Affairs Manager, Agricultural Biotechnology
PA to the Secretary General, IT Manager
Director, Industrial Biotechnology
@DelphineCarron
@joannadupont
Catherine De Feyter
Miriam Gargesi
Violeta Georgieva
Senior Manager, Finance, HR and Office Administration
Director, Healthcare Biotechnology
Officer, Agricultural Biotechnology
@c_defeyter
@mgargesi
@VioletaGeor
22
Katarzyna Jasik
Riccardo Mezzasalma
Project Coordinator, Industrial Biotechnology
Communications Manager, Agricultural Biotechnology
Officer, Healthcare Biotechnology
@bioscience_info
@KasiaJasik
@RiccardoMezzasa
MĂŠlanie Moxhet
Antoine Peeters
Cosmin Popa
Assistant, Administration and Communications
Manager, Industrial Biotechnology and EU Projects
Manager, Communications and National Associations
@MelaMox
@apeeters
@co5min_popa
Ioana Popescu
Pedro Narro Sanchez
Beat Späth
Officer, Industrial Biotechnology
Public Affairs Manager, Agricultural Biotechnology
Director, Agricultural Biotechnology
@ipopescu1
@pedroraulnarro
@BeatSpath
23
Review of year past & future outlook
Claire Gray
EuropaBio Members Our membership includes a wide range of corporate members and industry associations involved in biotechnology throughout Europe. EuropaBio has 60 corporate and 13 associate members and BIO Regions and 16 national biotechnology associations - representing some 1800 small and medium-sized enterprises across Europe.
Review of year past & future outlook
Corporate Members AbbVie
Corbion Purac
Knowledge Transfer Network Ltd
Protaffin Biotechnology AG
Alexion
CSL Behring
Amgen
Dow AgroSciences
KWS
PsiOxus Therapeutics LTD
ARD
DSM
Leitat Technology Center
Areta International
DuPont de Nemours
Limagrain
Autifony Therapeutics
Eli Lilly
MerckSerono
BASF
Erydel SPA
Monsanto
Baxter
Erytech Pharma
MSD Europe
Bayer
E-Therapeutics
Nanobiotix
BBB Therapeutics BV
Evonik
NatureWorks
Swedish Orphan Biovitrum
BioAmber
Gensight Biologics
Novamont
Syngenta
Biogen
Genzyme
Novartis
Transgene
Biomarin
GlaxoSmithKline
Novo Nordisk
uniQure NV
BIO-ON srl
Global Bioenergies SA
Novozymes
Vitromics Healthcare Holding B.V
Biosyntia ApS
Intrexon Actobiotics NV
Orphan Europe
Clariant Produkte GmbH
Keygene
Pfizer
Raptor Pharmaceuticals Europe BV Roquette Frères Sanofi Pasteur MSD Shire Solvay
ZeClinics
24
Associate Members and BIO Regions Expert Services & Advice in Healthcare BVBA
Perseus
Cambridge Biomedical Consultants LTD
Industries et Agro-Resources
SFL Services
Deerfield Management Company LP
IQX
TNO
Dr Regenold Gmbh
NestlĂŠ
Voisin Consulting
European Organisation for Research and Treatment of Cancer
National Associations Belgium | Bio.be
Lithuania | Lithuanian Biotech Association
Denmark | Dansk Biotech
The Netherlands | HollandBIO
Finland | FIB
Norway | Norwegian Bioindustry Association
France | France Biotech
Spain | ASEBIO
Germany | BIO Deutschland
Sweden | SwedenBio
Germany | DIB
Switzerland | Swiss Biotech Association
Ireland | IBIA
Switzerland | scienceindustries
Italy | Assobiotec
United Kingdom | BIA
25
Review of year past & future outlook
BIO.NRW
Review of year past & future outlook
Design and graphic production: Oktan Stavanger – www.oktanstavanger.no Printed by: Drukkerij Geers Offset EuropaBio team photos by: Vivian Hertz – www.vivianhertz.be View online version at: http://biotechaddress.europabio.org
26
Review of year past & future outlook
27
EuropaBio Avenue de l’Armée 6, 1040 Brussels (Belgium) Tel +32 2 735 03 13 Fax +32 2 735 49 60 Follow us on Twitter, Facebook and LinkedIn